Business Context and Reporting Period
This Form 6-K filing by Hutchison China Meditech Limited (HUTCHMED) covers the period for the month of January 2020, presenting unaudited condensed consolidated interim financial information for the nine months ended September 30, 2019, compared to the same period in 2018. The company operates through two primary segments: an Innovation Platform focused on drug development and a Commercial Platform focused on the distribution and sale of pharmaceutical products.
Key Financial Metrics
| Metric (Nine Months Ended Sept 30) | 2019 (US$'000) | 2018 (US$'000) |
|---|---|---|
| Revenues | 151,546 | 161,001 |
| Cost of Sales | (116,812) | (105,116) |
| Gross Margin % | 22.9% | 34.7% |
| Net Loss | (74,691) | (55,538) |
| Net Loss Attributable to Company | (76,462) | (58,269) |
| Net Cash Used in Operating Activities | (63,526) | (18,911) |
| Cash and Cash Equivalents (Sept 30, 2019) | 97,082 | 115,591 |
| Total Liquidity (Cash + Short-term Investments + Unutilized Facilities) | 347,900 | N/A |
Note: Total liquidity as of September 30, 2019, includes US$201.6 million in cash/short-term investments and US$146.3 million in unutilized bank facilities.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by 5.9% to US$151.5 million. This was driven by a significant 67.2% drop in Innovation Platform revenue (from US$32.9 million to US$10.8 million) due to the absence of a US$12.1 million milestone payment from Eli Lilly in the prior period and reduced clinical service fees.
- Commercial Growth: Commercial Platform revenue increased by 9.8% to US$140.7 million, led by a 16.1% rise in Prescription Drugs sales (US$114.9 million). This growth included US$7.3 million from the commercial launch of Elunate but was partially offset by a US$15.0 million decrease in Seroquel revenue following the termination of its distribution agreement in May 2019.
- Expense Increases:
- R&D Expenses: Increased 13.5% to US$100.7 million (66.5% of revenue) due to expanded clinical activities for candidates including savolitinib and surufatinib.
- Administrative Expenses: Increased 37.7% to US$30.3 million (20.0% of revenue), primarily due to US$5.2 million in legal and professional fees related to capital markets transactions.
- Cost of Sales: Increased 11.1% to US$116.8 million, raising the cost of sales ratio from 65.3% to 77.1% of revenue.
- Equity Earnings: Equity in earnings of equity investees increased significantly from US$11.1 million to US$30.5 million. This was largely due to the prior period including a US$18.8 million net loss from Nutrition Science Partners (due to an impairment), which was not present in the current period. The company acquired the remaining 50% of Nutrition Science Partners in December 2019.
Outlook, Risks, and Management Commentary
- Liquidity Position: Management believes current cash, short-term investments, and bank borrowings are sufficient to meet anticipated needs for at least the next 12 months. However, additional financing may be required to fund the Innovation Platform's clinical development efforts.
- Debt Activity: As of September 30, 2019, there were no outstanding bank borrowings. In October 2019, the company drew down US$26.9 million from a term loan facility. Unutilized bank facilities totaled US$146.3 million as of September 30, 2019.
- Risks and Contingencies:
- Dividend Restrictions: PRC regulations restrict the ability of subsidiaries to transfer net assets as dividends, loans, or advances. Approximately US$7.3 million of net assets were restricted as of September 30, 2019.
- Joint Venture Dividends: Cash held by non-consolidated joint ventures is only accessible via dividends, which are subject to partner agreement and profitability, creating uncertainty for future liquidity.
- Capital Needs: The Innovation Platform historically operates at a loss and requires significant investment over prolonged periods.
Investor Verification Checklist
- Verify the sustainability of Commercial Platform revenue growth following the discontinuation of the Seroquel business and the initial launch of Elunate.
- Confirm the timeline and funding requirements for the expanded clinical programs (savolitinib, surufatinib, HMPL-523, HMPL-689) driving the 13.5% increase in R&D expenses.
- Assess the impact of the US$5.2 million increase in legal and professional fees on future administrative cost structures.
- Review the terms and covenants of the new US$26.9 million term loan drawn in October 2019 and the status of the US$146.3 million in unutilized facilities.
- Monitor the integration and financial performance of Nutrition Science Partners following the acquisition of the remaining 50% stake in December 2019.